Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
Date: 10 November 2025
To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293
Dear Sir / Ma’am,
The Secretary
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol : SURAKSHA
Reg: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
Sub: Presentation to be made at the Analyst(s) / Investor(s) Meet/ Conference- Earnings Call
Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 05 November 2025 regarding schedule of Analyst(s)/ Investor(s) Meet /Conference i.e Earnings Call on Tuesday, 11 November 2025 at 2.00 pm (IST), we hereby enclose a copy of Investor Presentation on the unaudited (standalone and consolidated) financial results of the Company for quarter and six months ended 30 September 2025.
The Investor Presentation will be exhibited at the aforesaid Earnings Call and the same will be made available on the website of the Company at www.surakshanet.com.
Please note that the schedule of the aforesaid Earnings Call is subject to change. The changes might happen due to exigencies on the part of the Company/ Analyst(s)/ Investor(s).
This may please be informed to all the concerned.
For Suraksha Diagnostic Limited
_________________ Mamta Jain Company Secretary & Compliance Officer
Encl: As above
Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town,
Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750
SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q2 & H1 FY26
Safe Harbor Statement
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
Suraksha Diagnostic Limited| Investor Presentation
2
Q2 & H1 FY26 Highlights
Management Commentary on Q2 and H1 FY26 Results
We added 5 new centres in Q2 FY26, taking our total centre count to 63 (including 2 Fetomat centres). This quarter also marked a major milestone for us with the launch of Suraksha Genomics, a dedicated vertical offering cutting-edge genetic and molecular testing services.
Our progress with respect to market position and margins is also getting market recognition, as reflected in the recent upgrade to our credit ratings by a leading credit rating agency.
In Q2 FY26, our revenue rose by 17% YoY, reaching ₹796 million. In terms of profitability, our 42 mature centres have an EBITDA margin of 37-38% but our 21 new centres (15 centres are less than a year old) impact the overall EBITDA margin. As our new centres mature and economies of scale set in, we expect our margins to return to normal levels.
We will continue to remain prudent in our expansion journey and delivering value to our esteemed shareholders.
Ritu Mittal, Joint Managing Director & CEO
Suraksha Diagnostic Limited| Investor Presentation
4
Business at a Glance
as of 30 September 2025
8
Labs
63
0.71 million
4.13 million
₹ 189 million
Patients Served (H1 FY26)
Tests Performed (H1 FY26)
Revenue per lab (H1 FY26)
16
27
Diagnostic Centres
MRI Machines
CT Machines
173
Collection Centres
4
NABL accredited labs*
352
Doctors
₹ 2,120
Revenue per patient (H1 FY26)
₹ 695
EBITDA per patient (H1 FY26)
Note: * National Accreditation Board for testing and calibration Laboratories (NABL) Suraksha Diagnostic Limited| Investor Presentation
5 5
Key Financial Performance for Q2 FY26
Total Income (₹ million)
EBITDA (₹ million)
PAT (₹ million)
36.7%
34.0%
31.7%
15.2%
12.6%
11.2%
+17%
735
796
681
+2%
247
250
245
102
-13%
92
88
Q2 FY25
Q1 FY26
Q2 FY26
Q2 FY25
Q1 FY26
Q2 FY26
Q2 FY25
Q1 FY26
Q2 FY26
Suraksha Diagnostic Limited| Investor Presentation
6
Key Financial Performance for H1 FY26
Total Income (₹ million)
EBITDA (₹ million)
PAT (₹ million)
+18%
1,531
1,299
36.3%
32.8%
14.0%
11.9%
+7%
496
462
+1%
178
180
H1 FY25
H1 FY26
H1 FY25
H1 FY26
H1 FY25
H1 FY26
Suraksha Diagnostic Limited| Investor Presentation
7
Key Operating Metrics for H1 FY26
Number of Centres
Number of patients (million)
Number of Tests (million)
63
51
0.71
0.61
4.13
3.29
H1 FY25
H1 FY26
H1 FY25
H1 FY26
H1 FY25
H1 FY26
Revenue / Patient (₹)
2,099
2,120
EBITDA / Patient (₹)
761
695
Suraksha Diagnostic Limited| Investor Presentation
H1 FY25
H1 FY26
H1 FY25
H1 FY26
8 8
Statement of Profit & Loss (Consolidated)
Particulars (₹ million)
Revenue from Operations
Other Income
Total Revenue
Cost of Material Consumed
Employee Benefit Expenses
Other Expenses
Impairment Loss
EBITDA
EBITDA Margin (%)
Depreciation
Finance Cost
Profit before Tax & Exceptional Item
Exceptional Item
Profit before Tax
Profit before Tax (%)
Tax
Profit After Tax
PAT Margin (%)
EPS
Suraksha Diagnostic Limited| Investor Presentation
Q2 FY26
Q2 FY25
Y-o-Y
Q1 FY26
Q-o-Q
787.29
8.51
795.80
89.01
133.92
321.18
2.05
249.66
31.7%
101.43
27.76
120.47
0.00
120.47
15.3%
32.19
88.28
11.2%
1.73
667.54
13.13
680.67
79.31
110.21
242.64
3.43
245.07
36.7%
87.49
21.25
136.33
0.00
136.33
20.4%
34.77
101.56
15.2%
1.94
16.9%
1.9%
-11.6%
-11.6%
-13.1%
725.86
9.06
734.92
87.51
127.75
282.01
-8.90
246.56
34.0%
94.82
27.05
124.69
0.00
124.69
17.2%
32.94
91.75
12.6%
1.80
8.3%
1.3%
-3.4%
-3.4%
-3.8%
H1 FY26
1,513.15
17.57
1,530.72
Y-o-Y
H1 FY25
1,274.85
24.30
1,299.15
17.8%
176.51
261.66
603.19
-6.86
496.22
32.8%
196.26
54.81
245.16
0.00
245.16
16.2%
65.13
180.03
11.9%
3.53
145.68
214.00
472.17
5.02
462.28
36.3%
177.42
43.41
241.46
0.00
241.46
18.9%
63.24
178.22
14.0%
3.43
7.3%
1.5%
1.5%
1.0%
9
Balance Sheet (Consolidated)
Particulars (₹ million)
Assets
Non-current assets
Property, plant and equipment
Capital work-in-progress
Right-of-use assets
Other intangible assets
Intangible Assets under Development
Financial assets
Investments
Other financial assets
Non-current tax assets (net)
Other non-current assets
Total non-current assets
Current assets
Inventories
Financial assets
Trade receivables
Cash and cash equivalents
Bank balances other than cash and cash equivalents
Other financial assets
Other current assets
Total current assets
Total Assets
Suraksha Diagnostic Limited| Investor Presentation
H1 FY26
FY25
Particulars (₹ million) Equity
H1 FY26
FY25
1,669.81
18.81
1,042.09
52.31
9.05
-
150.51
44.08
81.60
1,471.37
100.99
742.90
15.00
4.93
10.00
426.91
16.28
75.33
3,068.26
2,863.71
84.46
80.49
136.28
21.07
414.87
10.10
67.44
734.22
138.12
22.47
178.59
25.30
26.56
471.53
3,802.48
3,335.24
Equity share capital Instruments entirely equity in nature Other equity Equity attributable to owners of the parent Non Controlling interest
Total equity Liabilities Non-current liabilities Financial liabilities
Borrowings Lease liabilities
Provisions Deferred tax liabilities (net)
Total non-current liabilities Current liabilities
Financial liabilities
Borrowings Lease liabilities Trade payables
Total outstanding dues of micro enterprises and small enterprises Total outstanding dues other than above micro enterprises and small enterprises Other financial liabilities
Other current liabilities Provisions Current tax liabilities (net)
Total current liabilities Total equity and liabilities
104.16 -
2,199.75 2,303.91 -9.69 2,294.22
- 7.63 1,013.12 9.39 60.33 1,090.47
19.35 136.85 -
104.16 - 2,008.24 2,112.40 (10.09) 2,102.31
- 28.75 712.28 10.22 54.51 805.77
29.50 118.38 -
12.46
19.67
151.41 67.59 28.27 1.33 0.53 417.79 3,802.48
116.76 107.72 33.80 1.25 0.08 427.17 3,335.24
10
Statement of Cash Flows (Consolidated)
Particulars (₹ million) Profit before Tax
Adjustment for Non-Operating Items
Operating Profit before Working Capital Changes
Changes in Working Capital
Cash Generated from Operations
Less: Income Taxes paid
Net Cash from Operating Activities
Purchase of property, plant & equipment and other intangible assets
Proceeds from sale of property and equipment
Investment in company
Investments in deposits with banks
Acquisition of subsidiary, net of cash acquired
Interest received on bank deposits
Cash Flow from Investing Activities
Contribution of non-controlling interests
Proceeds of borrowings
Repayment of borrowings
Payment of lease liabilities
Others
Cash Flow from Financing Activities
Net increase/ (decrease) in Cash & Cash equivalents
Add: Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period
Suraksha Diagnostic Limited| Investor Presentation
H1 FY26
245.16
236.54
481.70
-27.60 454.10
-87.17
366.93
-234.61
0.92
-
32.02
-32.71
16.33
-228.05
-
-
-33.28
-114.93
-2.06
-150.27
-1.40
22.47 21.07
H1 FY25
241.46
209.53
450.99
-35.33 415.66
-42.82
372.84
-199.09
1.50
-
-72.63
-
18.05
-252.17
1.00
-
-18.00
-103.97
-4.65
-125.61
-4.93
25.20 20.27
11
EBITDA Margin (%) Breakdown by Center Age
Q1 FY26
Q2 FY26
Overall EBITDA: 34.0%
Overall EBITDA: 31.7%
42 centres > 2 yrs
6 centres 1 yr to 2 yrs
15 centres < 1 yr
38.2%
6.6%
-57.7%
37.0%
13.3%
-50.3%
EBITDA Margin (%)
Suraksha Diagnostic Limited| Investor Presentation
12
Key Developments
Expanded Offerings Through Strategic Acquisition
ABOUT FETOMAT
•
•
•
•
Incorporated in May 2021, Fetomat Wellness Private Limited (“Fetomat”) is a network of fertility and pregnancy care clinics
Fetomat focuses on pregnancy care, women’s ultrasound scans, prenatal diagnostics, genetic counselling and medical training for doctors
Fetomat is one of Eastern India’s leading centers for fetal and maternal medicine and operated 2 centers as of 31 March 2024
For FY24, Fetomat’s turnover was ₹ 4.11 crore with an EBITDA of ₹ 0.56 crore
Key Highlights of Strategic Investment
In March 2025, the Board approved a proposal for a strategic investment in Fetomat
Upon deal completion on 09 April 2025, we held 63% stake in Fetomat
This strategic acquisition will help integrate fetal medicine expertise into our existing healthcare framework
The synergies with Fetomat will enhance innovation in fetal medical diagnostics, strengthening our industry position
Suraksha Diagnostic Limited| Investor Presentation
14
Genomics could be the Next Growth Lever
About Genomics Vertical
Global Genetic Testing Market Size ($ billion)
186.64
•
•
•
•
In July 2025, we announced the launch of Suraksha Genomics, a new vertical for advanced genetic and molecular testing services
Suraksha Genomics offers robust infrastructure and critical capabilities across prenatal diagnostics (QF-PCR, Karyotyping, FISH, Microarray, NIPT), inherited disease analysis (including single-gene mutation detection and whole exome sequencing), pharmacogenomics, and oncology-focused molecular panels
Focused on scaling into high-impact domains such as whole genome and metagenomic testing, AI integration and laying the groundwork for population-scale genomic screening initiatives
Aim to contribute to national priorities such as rare disease diagnosis, newborn screening, and preventive genomics, while also expanding research and public health initiatives
38.77
Suraksha Diagnostic Limited| Investor Presentation
2024
2035E
15
Strategy & Expansion
Expansion Plans – Centres FY26
Breakdown of Launches By Center Age and Location
Hub Centre
Spoke Centre
Public Private Partnership (PPP)
Q1 FY26
Q2 FY26
1 Baruipur
1 Ranaghat
4 Naihati, Shantipur, Gorabazar, Kanchrapara
1 S. D. Hospital, Durgapur
3 Fetomat - 2 & Ekbalpur
1 S. D. Hospital, Kharagpur
H2 FY26*
3 Mukundapur, Dhanbad & Berhampur
5 Shyambazar, Sonarpur, Belghoria, Krishnagar-2 & AIIR-2
1 Calcutta Medical College, Kolkata
Note: * We plan to open 9 centres in H2 FY26 Suraksha Diagnostic Limited| Investor Presentation
17
Centre Expansion in H1 FY26
Suraksha Diagnostic Limited| Investor Presentation
18
Upcoming Centres in H2 FY26
Suraksha Diagnostic Limited| Investor Presentation
19
Company Overview
Vision, Mission and Values
Medium-term
Long-term
Vision
We aspire to metamorphise the Company into the most reputable and cutting-edge diagnostic facility, providing precise, prompt, affordable diagnostic services that will promote early detection and long-term wellness for everybody
Our vision is to be the most trusted and innovative diagnostic centre and set the standard for diagnostics in the future by utilising state-of-the-art technology with knowledgeable interpretation by expert professionals, accurate reporting and smooth patient experiences
To become the premier and most reliable diagnostic facility in India
To establish an accurate and cost- effective diagnostic facility
To offer our patients a better quality of reporting service
To achieve high governance standards
Mission
To have excellent financial results
To enhance the lives of people centred around Suraksha
To harness the latest advancements in diagnostic technology to provide quick, reliable results
Precise diagnostic results are at the heart of Suraksha’s approach
Values
The benchmark for Suraksha’s success is customer satisfaction and we aim to make diagnostic services accessible and affordable early for detection, effective treatment and long-term health by creating a safe space for accurate health evaluations
supporting
all,
At Suraksha, integrity in business is are fundamental. We committed to maintaining transparency and upholding the highest standards of business ethics in all our dealings
We recognise the value of time and its optimum utilisation for timely decision-making
Suraksha Diagnostic Limited| Investor Presentation
21
Evolution to the Largest Integrated Diagnostic Chain in East India
Built fully comprehensive diagnostic centre, under brand ‘Suraksha’
1 centre
5 centres
Received second round of funding from OrbiMed
Exit of Lighthouse Funds
4 Labs
25 centres
IPO and listing on BSE and NSE
9 Labs
53 centres
63 centres
1992
2007
2010
2013
2016
2020
2024
2025
Launched the first centre of the Company
Received first round of funding from PE investor Lighthouse Funds
Acquisition of 2 pre- existing diagnostic centres in Kolkata from Future Medical & Research Trust
Acquisition of Fetomat Wellness Private Limited (63% stake)
Launch of Suraksha Genomics
Suraksha Diagnostic Limited| Investor Presentation
22
Deeply Entrenched in the Vital Geography of West Bengal
•
•
•
4th most populous state in India Fragmented market with low penetration of chained diagnostic centers Accounted for 95.5% of FY25 Revenue from operations
Bihar
Assam
West Bengal
Meghalaya
61 Centers in West Bengal
No. of centres
>10 centres
4 to 10 centres
3 centres
2 centres
1 centre
Population Legend
No. of people
>8.5 mn
6.0 – 8.5 mn
4.0 – 6.0 mn
2.0 – 4.0 mn
<2.0 mn
2
1
1
4
5
26
3
14
3
1
1
Suraksha Diagnostic Limited| Investor Presentation
23
Hub & Spoke Operating Model
Modalities Offered
Key Stats
MRI
Gastroenterology
Dexa
OPG
Mammo
CT Scan
Neurology
USG
X-Ray
Cardiology
Pathology
CT-Scan
Neurology
USG
X-Ray
Cardiology
Pathology
s e r t n e C b u H
s e r t n e C e k o p S
Large
Centres
Medium Centres
Small Centres
# of doctors & employees / centre
Area
30-40
5,000 – 8,000 sq. ft
20-25
2,500 – 5,000 sq. ft
12-15
1,500 – 3,500 sq. ft
USG
X-Ray
Cardiology
Pathology
Suraksha Diagnostic Limited| Investor Presentation
24
Demonstrated success in Kolkata region with significant potential for future growth2
…..With Demonstrated Success
Operational Network(1)
1 Central Lab
7 Satellite Labs
16 Hub Centres
(co-located with hub centres)
(equipped to conduct all pathology sample collection, basic and advanced radiology tests)
12 Medium Centres
30 Small Centres
5 PPP
173 Sample Collection Centres
Spoke Centres
(equipped to conduct all pathology sample collection and certain basic & intermediate radiology tests)
Enhanced brand penetration through ability to serve more customers
Unlocks economies of scale
Hub centres Offers pathology tests, basic & advanced radiology tests
Spoke centres Offers pathology tests, basic and intermediate radiology tests
Note: 1) as of 30 September 2025; 2) Map illustrating t he ‘hub and spoke’ model in the diagnostic centre network in Greater Kolkata, representing cl usters formed by combining t he hub cent res and spoke centres
Suraksha Diagnostic Limited| Investor Presentation
25
Well-established Operational Network - Greater Economies of Scale
Report Flow
Patient
Image/Report Flow
Image Flow
Patients Flow
Doctor
Polycli ni c Doct or
Hospi tal
Customers
Samples
Sample Flow
Patient Flow
Suraksha Diagnostic Limited| Investor Presentation
P.A.C.S (Software)
RAD (Scrutiny)
IMAGE (Report)
#16
Hub Centre
#42
Spoke Centre
Collection Centre #173
Home Coll ecti on
#1 Flagship Reference Lab
#7
SATELLITE LAB
26
Well Equipped Clinical Infrastructure
Suraksha Diagnostic Limited| Investor Presentation
27
Customer Convenience Through Value Added Services
Value Added Services enhancing customer experience and convenience
Home Collection
Allows samples to be collected from the consumers’ locations, such as their homes or offices
SMS Alerts
Customers receive an SMS to download the report through email or web portal
Polyclinic Chambers
Polyclinic chambers hosting doctors providing out-patient consultation
Customer Centric Approach
Polyclinic Chambers
Online Bookings
More convenience through online test bookings, consultations and digital test results
Suraksha Diagnostic Limited| Investor Presentation
Online Bookings
Customers can book appointments and access test reports online
28
Positioned to Leverage IT Infrastructure
Suraksha’s Integrated System for Diagnostics
LIMS Integration
RIS and PACS Workflow
Advanced Imaging Tools
ERP-enabled Operations
Error Reduction and Turnaround Time
Our Laboratory Information Management System (LIMS) streamlines sample processing and report delivery. It ensures accuracy through barcoded labels and bi- directional analyser integration
The Radiology Information System (RIS) and PACS streamline imaging workflows. They integrate with registration and dispatch systems for smooth operations
PACS includes DICOM viewers with MIP, MPR, and 3D tools. These support high-quality image analysis across modalities and locations
Our ERP system handles billing, inventory, procurement, and equipment use. It drives efficiency across all diagnostic centers
Automation reduces errors and improves turnaround tracking. It ensures reliable and consistent service across the network
Suraksha Diagnostic Limited| Investor Presentation
29
Key Differentiating Factors
Polyclinic
Diversified in terms of revenue from services
% of H1 FY26 Revenue
160+
Chambers1
1,000+
Doctors1
48%
46%
6%
Pathology
Radiology
Other
Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers
Other includes Revenue from Doctor Consultancy and Pharmacy
Note: 1) as of 30 September 2025
Suraksha Diagnostic Limited| Investor Presentation
30
Experienced Board Of Directors
Dr. Somnath Chatterjee Chairman & Joint Managing Director
▪ Associated with Suraksha since
incorporation; 32+ years of experience in medical and diagnostics business
▪ Holds bachelor’s degree in medicine and surgery from University of Calcutta and is registered with West Bengal Medical Council
Ritu Mittal Joint Managing Director & Chief Executive Officer
▪ Associated with Suraksha since
incorporation; 28+ years of experience in the medical and diagnostics business ▪ Cleared the examination for a bachelor’s
degree in commerce from the University of Calcutta
Mr. Satish Kumar Verma Non-Executive, Non-Independent Director
▪ 40+ years of experience in management ▪ Holds a bachelor’s degree in mechanical
engineering and post-graduate diploma in engineering from Punjab University
Mr. Pradip Kumar Dutta Independent Director
Mr. Siddhartha Roy Independent Director
▪ Several years of work experience. Currently, an advisor to board at Simyog Technology
▪ 39+ years of experience ▪ Holds bachelor’s degree in law from
▪ Holds B.Tech degree in electronics &
electrical communication engineering from IIT, Kharagpur; a MS degree and doctorate in philosophy from the University of Maryland
Suraksha Diagnostic Limited| Investor Presentation
Calcutta University, and also a member of the Institute of Company Secretaries of India
Mr. Dharam Chand Dharewa Independent Director
▪ 30+ years of experience ▪ Holds bachelor’s degree in commerce from G.D. Binani Mahavidyalaya, and is practicing chartered accountant since 1987
Ms. Ishani Ray Independent Director
▪ 27+ years of experience in finance ▪ Holds bachelor’s degree and master’s
degree in commerce from the University of Calcutta; she is an associate of the Institute of Chartered Accountants of India
31
Dynamic And Diverse Management Team to Deliver Next Phase of Growth
Ravindra K S Group Chief Financial Officer
Mamta Jain Company Secretary & Compliance Officer
Niren Kaul Chief Sales Officer
▪ Professional with over 20 years of extensive experience in the finance sector including the role of Group CFO at Medica Hospitals Group, Group Finance Controller at Narayana Hrudayalaya Limited and Group Manager- Finance at Aditya Birla Nuvo Limited
▪ He has a Bachelor’s in Commerce from Kuvempu
University and is a member of the Institute of Chartered Accountants of India
▪ 9+ years of experience including with VISA International
Limited and Dollar Industries Limited
▪ Holds a bachelor’s degree in commerce from University of Calcutta, associate member of ICSI, member of the ICWAI and diploma in business administration from Symbiosis Centre for Distance Learning
▪ 22+ years of experience, including with Bharti Hexacom
Limited and Bharti Infratel Limited
▪ Holds a bachelor’s degree in electrical engineering from
Pandit Ravishankar Shukla University, Raipur and master’s degree in business administration from University of Pune
Balgopal Jhunjhunwala Regional Business Head
Sangeeta Chakraborty General Manager, Operations
▪ 15+ years of experience
▪ 26+ years of experience
▪ Holds a bachelor’s degree in commerce from University of
Calcutta
▪ She holds a Bachelor's degree in Arts from the University of Calcutta. She previously worked in the healthcare industry, managing inventory operations and contributing to process efficiency and supply chain coordination
Suraksha Diagnostic Limited| Investor Presentation
32
Marquee Shareholders Invested in our Story
Shareholding Pattern as at 30 September 2025
13.72%
48.98%
21.99%
15.31%
Promoter & Promoter Group
FIIs
DIIs
Others
Source: BSE
DIIs include Mutual Funds, AIFs and Central / State governments FIIs include Foreign Direct Investments and Foreign Portfolio Investors Others include Retail, NRIs, Bodies Corporate and others
Suraksha Diagnostic Limited| Investor Presentation
33
Key Awards & Recognition
2017
2019
2021
Best quality in service delivery(1)
Best customer service in healthcare(1)
Business leader of the year(2)
2021
Awards & certificate of excellence(3)
2022
Outstanding diagnostic chain of eastern India(4)
2023 Certificate of excellence in exemplary trust & commitment towards diagnostic services(5)
2025
Award for Talent Management (Leadership)(6)
2025
Outstanding Diagnostic Chain of Eastern India(7)
2025
Acknowledgment for Strides in Genomics(4)
Note: 1) Awarded by ABP News; 2) by the W orld Leadership Congress & Awards; 3) by Zee24 Ghanta; 4) by ABP Ananda; 5) at the Health Conclave 2023 organized by Zee24 Ghant a; 6) By EIILM, Kolk ata; 7) by R. Bangala
Suraksha Diagnostic Limited| Investor Presentation
34
Strategy & Outlook
Leveraging Strengths to Drive Competitive Advantage
Largest diagnostic chain with a dominant position in Eastern India; well-positioned to benefit from the high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North-Eastern India
Technologically advanced clinical infrastructure and trained personnel ensuring high quality and reliable diagnostic services
Track record of profitability and consistent financial performance
Integrated diagnostics provider with one-stop solution offering pathology & radiology testing, and medical consultation services
High brand recall and commitment to superior quality, driving high individual consumer business share and customer retention
Management team with robust industry experience
Suraksha Diagnostic Limited| Investor Presentation
36
Strategic Levers to Drive Future Growth
Expand footprint in Eastern and North-Eastern India through organic as well as inorganic route
Strengthen B2B and institutional partnerships to access new customer segments
Build on brand equity and service quality to drive customer retention and deliver growth
Enhance one-stop diagnostic model by augmenting medical consultation services’ share
Invest in technology to enhance diagnostic accuracy, lower turnaround time and elevate customer experience
Leverage experienced leadership for strategic decision-making and operational efficiency
Suraksha Diagnostic Limited| Investor Presentation
37
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Consolidate leading position in the core geography
Expand in adjacent geographies of Eastern and North-Eastern India
Supplement organic growth with selective acquisitions
Open additional diagnostic centres and increase franchisee partnerships with local entrepreneurs
Enhance the laboratory capacity and test menu by adding latest technologies
Increase home collection services
Identify key locations in Eastern and North-Eastern India
Replicate the (a) ‘hub and spoke’ model to unlock economies of scale (b) polyclinic model to drive higher number of patient footfalls
Build spoke centers around the existing hub centers in Bihar, Guwahati and Meghalaya
Selective acquisitions of and/or strategic partnerships with local diagnostic centres across Eastern and North-Eastern India
Factors while evaluating acquisition targets • Brand recognition • Customer base • Technical capability and resources
Set up more hub centres to form new clusters, and spoke centres in existing clusters
Wider geographic reach will expand the customer base as well as improve the profitability by allowing to better leverage the infrastructure
Leverage technology to elevate customer experience
Increase share of medical consultation services at diagnostic centres
Engage in Business-to-business (“B2B”) and corporate partnerships
Create a convenient one-stop solution through integration of digital technology, artificial intelligence and machine learning
Increase the touch points and engagement with customers through digital and technological initiatives
Set up more polyclinics in the existing diagnostic centres, and increase the number and specialties of doctors associated
Enhance revenue from the B2B segment to further diversify revenue mix and increase customer base & brand penetration
Achieve higher footfalls, tests per patient, and average revenue per patient
Actively seek institutional customers through referrals or internal lead-generation
Suraksha Diagnostic Limited| Investor Presentation
38
Industry Overview
Industry: Poised For High Growth; Shifting Towards Organized Market
Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28
Organized players gaining market share from standalone labs at a steady rate
CAGR 10-12%
1,275-1,375
860-870
FY24E
FY28P
Indian Diagnostic Industry (INR bn)
Pathology
56%
44%
Radiology
36-40%
13- 17%
45-49%
FY201
20- 24%
36-40%
35-39%
FY24E1
Diagnostic chains
Hospital Based
Standalone
Estimated break-up of the Indian diagnostics industry
Radiology expected to grow at a relatively faster pace
CAGR 9-11%
700-755
480-490
FY24E
FY28P
CAGR 11-13%
570-620
375-385
FY24E
FY28P
Radiology Market (INR bn)
Segment wise break-up of diagnostics market (FY24E)
Pathology Market (INR bn)
Source: CRISIL Report Note: 1) For FY20 & FY24E, Multiregional Chains account for 35-40% & 34-38% respect ively of the overall Diagnosti c Chains; For FY20 & FY24E, Regional Chains account for 60-65% & 62-66% respect ively of the overall Diagnosti c Chains
Suraksha Diagnostic Limited| Investor Presentation
40
Eastern India - An “Underserved” Market With Premium Pricing
Disparity in access to accredited testing services in Eastern(1) India relative to population needs
Region has the lowest number of NABH accredited hospitals
East India(1) market also offers premium pricing for diagnostic tests
2.50
430
1.62
1.60
Average: 1.61
187
227
0.96
North
South
West
East¹
North
South
West
Average: 179
50
East & North East
1
# NABL labs per mn population (Feb 2024)
# Region wise NABH accredited hospitals
70-80
55-65
80-90
80-90
South
North
East & North East1 Region-wise average diagnostic test expenditure(2) (INR)
West
East India(1) has the highest share of population, yet the lowest share of Indian diagnostics market
East India(1) diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28
West Bengal diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28
INR (Bn)
CAGR 10.5-12.5%
260-280
INR (Bn)
CAGR 10.5-12.5%
170-180
% share of population in East India, FY24E(1)
% share of East India(1) diagnostics market, FY24E
FY24E
FY28P
Source: CRISIL Report Note: 1) East including Northeast regi on is defined as: Bi har, Jharkhand, Odisha, West Bengal, Chhattisgarh: Sikkim, Arunacha l Pradesh, Assam, Tri pura, Mizoram, Nagaland, Manipur, Meghalay a; 2) For non-hospi tali zation
Suraksha Diagnostic Limited| Investor Presentation
61-63
FY24E
95-100
FY28P
41
Historical Financials and Operating Metrics
Consolidated Financial Performance – Historical
Total Income (₹ million)
EBITDA (₹ million)
PAT (₹ million)
25.0%
33.7%
33.8%
3.2%
10.6%
12.3%
+32%
2,223
2,559
1,937
+79%
736
851
475
310
+411%
231
61
FY23
FY24
FY25
FY23
FY24
FY25
FY23
FY24
FY25
Suraksha Diagnostic Limited| Investor Presentation
43
Consistent Performance Over the Years
Number of Centres
Number of Patients (million)
Number of Tests (million)
43
48
55
1.11
1.14
1.19
5.98
6.69
5.17
FY23
FY24
FY25
FY23
FY24
FY25
FY23
FY24
FY25
Revenue / Patient (₹)
EBITDA / Patient (₹)
ROE %
ROCE %
+24%
1922
2118
1712
+67%
647
715
427
16.29
14.09
21.46
23.30
4.32
9.05
FY23
FY24
FY25
FY23
FY24
FY25
FY23
FY24
FY25
FY23
FY24
FY25
Suraksha Diagnostic Limited| Investor Presentation
44
Statement of Profit & Loss (Consolidated)
Particulars (₹ million)
Revenue from Operations
Other Income
Total Revenue
Cost of Material Consumed
Employee Benefit Expenses
Other Expenses
Impairment Loss
EBITDA
EBITDA Margin (%)
Depreciation
Finance Cost
Profit before Tax & Exceptional Item
Exceptional Item
Profit before Tax
Profit before Tax (%)
Tax
Profit After Tax
PAT Margin (%)
EPS
FY25
2520.93
38.46
2559.39
295.19
428.90
962.55
21.86
850.88
33.8%
352.98
83.85
414.05
-
414.05
16.4%
104.27
309.78
12.3%
5.97
FY24
2187.09
35.51
2222.59
272.51
400.68
811.88
1.34
736.18
33.7%
325.98
87.88
322.31
7.79
314.53
14.7%
83.26
231.26
10.6%
4.43
FY23
1901.34
35.53
1936.87
274.04
398.19
789.85
474.49
25.0%
316.71
90.60
67.48
-
67.48
3.5%
6.83
60.65
3.2%
1.22
FY25 vs FY24
FY23-25 CAGR (%)
15.2%
15.0%
15.6%
33.9%
28.5%
31.6%
34.0%
126.0%
Suraksha Diagnostic Limited| Investor Presentation
45
Balance Sheet (Consolidated)
Particulars (₹ million)
Assets
Non-current assets
FY25
FY24
FY23
Particulars (₹ million) Equity
Property, plant and equipment
1,471.37
1,350.50
1,127.89
Capital work-in-progress
Right-of-use assets
Other intangible assets
Intangible Assets under Development
Financial assets
Investments
Other financial assets
Non-current tax assets (net)
Other non-current assets
Total non-current assets
Current assets
Inventories
Financial assets
Trade receivables
Cash and cash equivalents Bank balances other than cash and cash equivalents
Other financial assets
Other current assets
Total current assets
Total Assets
Suraksha Diagnostic Limited| Investor Presentation
100.99
742.90
15.00
4.93
10.00
426.91
16.28
75.33
13.13
754.09
10.76
-
-
84.49
18.31
46.27
23.91
809.69
14.49
-
-
131.56
21.41
2.49
2,863.71
2,277.56
2,131.44
80.49
66.78
61.62
138.12
22.47
178.59
25.30
26.56
471.53
88.75
25.20
46.80
21.62
525.03
528.77
-
18.73
724.49
-
21.70
680.51
3,335.24
3,002.05
2,811.95
Equity share capital Instruments entirely equity in nature Other equity Equity attributable to owners of the parent Non Controlling interest
Total equity Liabilities Non-current liabilities Financial liabilities
Borrowings Lease liabilities
Provisions Deferred tax liabilities (net)
Total non-current liabilities Current liabilities
Financial liabilities
Borrowings Lease liabilities Trade payables
Total outstanding dues of micro enterprises and small enterprises Total outstanding dues other than above micro enterprises and small enterprises
Other financial liabilities
Other current liabilities Provisions Current tax liabilities (net)
Total current liabilities Total equity and liabilities
FY25
FY24
FY23
104.16 - 2,008.24 2,112.40 (10.09) 2,102.31 - - - 28.75 712.28 10.22 54.51 805.77 - - 29.50 118.38 -
69.00 16.29 1,708.80 1,794.08 (2.62) 1,791.46 - - - 51.83 703.07 7.71 53.86 816.47 - - 34.54 115.33 -
69.00 16.29 1,473.97 1,559.26 (4.65) 1,554.61 - - - 84.36 719.28 4.51 65.78 873.93 - - 55.71 109.39 -
19.67
32.26
34.53
116.76 107.72 33.80 1.25 0.08 427.17 3,335.24
111.66 77.68 17.46 - 5.19 394.12 3,002.05
105.86 64.71 12.41 0.79 0.01 383.41 2,811.95
46
Statement of Cash Flows (Consolidated)
Particulars (₹ million)
Profit before Tax
Adjustment for Non-Operating Items
Operating Profit before Working Capital Changes
Changes in Working Capital
Cash Generated from Operations
Less: Income Taxes paid
Net Cash from Operating Activities
Purchase of property, plant & equipment and other intangible assets
Proceeds from sale of property and equipment
Investment in company
Investments in deposits with banks
Redemption of deposits with banks
Interest recveived on bank deposits
Cash Flow from Investing Activities
Proceeds of borrowings
Repayment of borrowings
Payment of lease liabilities
Others
Cash Flow from Financing Activities
Net increase/ (decrease) in Cash & Cash equivalents
Add: Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Suraksha Diagnostic Limited| Investor Presentation
FY25
414.05
428.61
842.67
-103.26
739.41
-105.82
633.59
-420.24
1.41
-10.00
-2.60
35.59
-395.84
-
-28.11
-207.00
-5.367
-240.48
-2.73
25.2
22.47
FY24
314.53
413.29
727.82
-36.9
690.92
-86.1
604.81
-446.94
17.73
-
-413.71
461.06
31.9
-349.95
5
-58.7
-195.55
-2.05
-251.30
3.58
21.62
25.2
FY23
67.48
397.12
464.6
48.29
512.89
-71.93
440.96
-131.67
6.61
-
-410.51
302.25
25.37
-207.95
20.5
-70.7
-180.12
-12.96
-243.28
-10.27
31.89
21.62
47
Company :
Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Email: investors@surakshanet.com
investors@surakshanet.com
Investor Relations Advisors :
MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services
Mr. Ashish Tendulkar ashish.tendulkar@in.mpms.mufg.com
Ms. Pooja Swami pooja.swami@in.mpms.mufg.com
Meeting Request
Link Link
Link
THANK YOU